Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.08
-C$0.01(-13.33%)
At close: 4:00 PM EDT
C$0.08
-C$0.01(-13.33%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume35.78K
Average Volume (3M)0.00
Market Cap
C$11.52M
Enterprise ValueC$26.82
Total Cash (Recent Filing)C$17.52K
Total Debt (Recent Filing)C$19.14M
Price to Earnings (P/E)―
Beta-3.40
Next Earnings
May 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,283,630
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginA positive gross margin indicates the company’s products can generate contribution before operating costs. The improvement from 2023 suggests better production economics, although the benefit remains insufficient to offset substantial operating expenses.
Asset Base ExpansionGrowth in the asset base may provide more operating capacity and support future production or product development. However, the value is constrained by negative equity and high leverage, so assets must be converted into revenue efficiently.
Specialized Cannabis Supply ModelA focused cultivation and extraction model gives PharmaCielo exposure to multiple regulated downstream applications rather than a single end market. This specialization could support future partnerships, though regulatory compliance and commercial execution remain essential.
Bears Say
Severe Revenue ContractionVery small and sharply declining revenue indicates weak demand, limited customer scale, or disrupted commercialization. Without sustained sales growth, the company cannot absorb fixed costs, fund operations internally, or establish a durable path to profitability.
Persistent Operating LossesDeep operating and net losses show that improved product-level economics have not translated into a viable company-wide model. Continued losses may require restructuring, cost reductions, or external funding before sustainable profitability can be demonstrated.
Stressed Balance Sheet And Cash BurnNegative equity, meaningful debt, and ongoing cash burn materially restrict financial flexibility. The company may face refinancing, dilution, or solvency pressure, while insufficient internally generated cash limits investment in growth and operations.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$11.52M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is May 31, 2027 which is in 284 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 211,283,630 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―